Rigel Pharmaceuticals

Rigel Pharmaceuticals

Yahoo Finance • 10 days ago

As U.S. profit margins near record highs, these small-cap stocks lead on profitability

[Growth bar graph] Dougal Waters As U.S. corporate profit margins remain near historic highs, investors are increasingly looking for companies that can translate strong operating performance into sustained earnings growth. Recent data fr... Full story

Yahoo Finance • 11 days ago

These small-cap healthcare stocks pair revenue growth with attractive valuations

[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images Healthcare stocks have remained in focus as investors look for companies that can deliver strong operational growth... Full story

Yahoo Finance • last month

Pfizer’s VEPPANU License With Rigel Adds New Angle To PFE Story

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Pfizer and its partners have granted Rigel Pharmaceuticals an exclusive license to commercialize V... Full story

Yahoo Finance • 2 months ago

Arvinas Q1 Earnings Call Highlights

Arvinas logo Key Points Interested in Arvinas, Inc.? Here are five stocks we like better. VEPPANU’s FDA approval was the quarter’s biggest milestone, with CEO Randy Teel calling it the first approval of a heterobifunctional PROTAC degrad... Full story

Yahoo Finance • 2 months ago

Rigel Pharma Signs Licensing Agreement With Arvinas And Pfizer For Veppanu

(RTTNews) - Rigel Pharmaceuticals, Inc. (RIGL) on Tuesday said it has entered into a global license agreement with Arvinas, Inc. (ARVN) and Pfizer Inc. (PFE) to develop, manufacture and commercialize beast cancer treatment Veppanu. Veppan... Full story

Yahoo Finance • 2 months ago

Why One Fund’s $4 Million Centerra Gold Exit Looks Like Profit-Taking Amid a 150% Rally

On May 8, 2026, CM Management reported selling its entire 200,000-share stake in Centerra Gold(NYSE:CGAU), an estimated $3.56 million trade based on quarterly average pricing. What happened According to a Securities and Exchange Commissi... Full story

Yahoo Finance • 2 months ago

This Fund Cashed Out of Preformed Line Products Amid a 150% Stock Surge

On May 8, 2026, CM Management disclosed in a U.S. Securities and Exchange Commission (SEC) filing that it sold its entire stake in Preformed Line Products(NASDAQ:PLPC), an estimated $6.39 million trade based on quarterly average pricing.... Full story

Yahoo Finance • 3 months ago

Stock Market Today, March 16: CytomX Therapeutics Surges After Positive Phase 1 Colorectal Cancer Data

CytomX Therapeutics(NASDAQ:CTMX), a biotech company that develops conditionally activated biologics for cancer treatment, closed Monday at $6.75, up 44.23%. The stock is jumping after releasing Phase 1 Varseta-M data in metastatic colorect... Full story

Yahoo Finance • 4 months ago

Rigel Pharmaceuticals GAAP EPS of $13.54 beats by $12.31, revenue of $69.8M beats by $1.1M

* Rigel Pharmaceuticals press release [https://seekingalpha.com/pr/20422791-rigel-provides-fourth-quarter-and-full-year-2025-financial-results-and-provides-business] (RIGL [https://seekingalpha.com/symbol/RIGL]): Q4 GAAP EPS of $13.54 be... Full story

Yahoo Finance • 4 months ago

Rigel Pharmaceuticals Q4 2025 Earnings Preview

* Rigel Pharmaceuticals (RIGL [https://seekingalpha.com/symbol/RIGL]) is scheduled to announce Q4 earnings results on Tuesday, March 3rd, after market close. * The consensus EPS Estimate is $1.20 [https://seekingalpha.com/symbol/RIGL/e... Full story

Yahoo Finance • 7 months ago

Rigel's R289 Shows Promising RBC Transfusion Independence In Phase 1b Trial In Lower-Risk MDS

(RTTNews) - Rigel Pharmaceuticals, Inc. (RIGL), a commercial-stage biotechnology company focused on hematologic disorders and cancer, announced encouraging updated data from its ongoing Phase 1b study of drug candidate R289 in patients wit... Full story

Yahoo Finance • 7 months ago

Eli Lilly Partner And Cancer Treatment Maker Nears Buy Point

This cancer treatment stock is nearing a buy point of a base after quarterly earnings. The Eli Lilly partner reports positive trial news. Continue Reading View Comments... Full story

Yahoo Finance • 8 months ago

Rigel Pharmaceuticals jumps on 2025 revenue guidance boost, Q3 beats

[Third Quarter Q3 Profits Stock Trading Chart 3D Background] filo * Rigel Pharmaceuticals (RIGL [https://seekingalpha.com/symbol/RIGL]) is up ~31% in Wednesday trading after increasing its full-year guidance outlook and releasing Q3 fin... Full story

Yahoo Finance • 8 months ago

After-Hours Gainers: VCYT, RIGL, NPCE, CDNA, And FBLG Post Notable Moves Following Q3 Results

(RTTNews) - Several healthcare and biotech names posted strong after-hours gains on Tuesday following the release of third-quarter earnings and updated guidance for the remainder of 2025. The session was marked by sharp price movements as... Full story

Yahoo Finance • 9 months ago

Rigel Pharmaceuticals Inc (NASDAQ:RIGL) Shows Explosive Growth, Fits Navellier's 'Little Book' Strategy

Rigel Pharmaceuticals Inc (NASDAQ:RIGL [https://www.chartmill.com/stock/quote/RIGL]) has become an interesting option for growth investors using the screening method from Louis Navellier's "The Little Book That Makes You Rich." This invest... Full story

Yahoo Finance • 10 months ago

RIGEL PHARMACEUTICALS INC (NASDAQ:RIGL) Combines High Growth Momentum with Strong Technical Setup

For investors aiming to merge fundamental momentum with technical accuracy, a multi-layered screening method can produce strong opportunities. By selecting for stocks with a High Growth Momentum Rating above 4, a Technical Rating above 7,... Full story

Yahoo Finance • 10 months ago

Rigel Pharmaceuticals Inc (NASDAQ:RIGL) Emerges as a Top Affordable Growth Stock

In the changing environment of equity investing, the search for growth at a reasonable price is a fundamental strategy for many investors. This method, often called "affordable growth" or GARP (Growth At Reasonable Price), tries to find co... Full story

Yahoo Finance • 10 months ago

RIGEL PHARMACEUTICALS INC (NASDAQ:RIGL): A Deep Value Stock with Strong Fundamentals

In value investing, finding stocks that trade below their intrinsic value while having good basic fundamentals is a key strategy. This method, based on the ideas of Benjamin Graham and later made famous by Warren Buffett, aims to find chan... Full story

Yahoo Finance • 10 months ago

KalVista Pharmaceuticals Stock Sees RS Rating Rise To 82

On Wednesday, KalVista Pharmaceuticals stock reached an important technical milestone, seeing its Relative Strength (RS) Rating jump into the 80-plus percentile with an improvement to 82, up from 79 the day before. Is KalVista Pharmaceutic... Full story

Yahoo Finance • 10 months ago

Rigel Pharmaceuticals Inc (NASDAQ:RIGL) Emerges as a Top Growth Stock on Navellier's Screening Model

Rigel Pharmaceuticals Inc (NASDAQ:RIGL [https://www.chartmill.com/stock/quote/RIGL]) has become an interesting candidate for growth investors using the screening method from Louis Navellier's "The Little Book That Makes You Rich." This inv... Full story